Wilson Sonsini - ECP

Biotech

Our Industry Coverage

Innovative and passionate; that's how we describe our biotech companies. From cutting-edge biopharmaceutical therapies to bioinformatics, we support our clients’ pursuit of excellence. Through their relentless drive to innovate, we work to protect pivotal intellectual property, navigate regulatory environments, and advise on financing strategy.

Industry Highlights

Celebrating our founders’ successes

2000

Illumina Completes IPO Worth $96 Million

Diagnostics & Research

2009

Genentech Acquired by Roche for $46.8 Billion

Pharmaceuticals

2010

Pacific Biosciences Raises $200 Million in IPO

Diagnostics & Research

2014

Xenon Pharmaceuticals Launches IPO

Drug Discovery, Pharmaceuticals

2016

BioCardia Unveils Reverse Merger

Pharmaceuticals

2017

Denali Therapeutics Makes Record BioTech IPO

Drug Discovery

2018

WuXi AppTec Raises $356 Million IPO

Diagnostics & Research

2018

Allakos Completes IPO Worth $135 Million

Drug Discovery, Pharmaceuticals

2019

IGM Biosciences Launches IPO

Biotechnology

2020

Applied Molecular Transport Closes IPO at $154 Million

Pharmaceuticals

2020

ORIC Pharmaceuticals Raises $138 Million IPO

Pharmaceuticals

2020

ALX Oncology Holdings Inc. Closes IPO at $186 Million

Immuno-Oncology

2021

Kinnate Biopharma Inc. Raises $276 Million IPO

Drug Discovery, Pharmaceuticals

2021

Tenaya Therapeutics Completes IPO Worth $207 Million

Biotechnology

2021

Ventyx Biosciences Closes IPO at $175 Million

Biotechnology, Pharmaceuticals

2022

Arcellx, Inc. Raises $124 Million IPO

Biotechnology

Attorneys

focused
on this
industry

See all ECP attorneys

Stacy
Kim

See all ECP attorneys

recent news

we want to share
with you

Firm Advises Investors on D3 Bio’s $62 Million Series A+ Financing

Firm Advises Investors on D3 Bio’s $62 Million Series A+ Financing

Client Highlights04/17/24
Firm Advises Novo Holdings on Obsidian’s Oversubscribed $160.5 Million Series C
See all news
See all news

other industries

we have covered